LFCM
LAB icon

Long Focus Capital Management’s Standard BioTools LAB Stock Holding History

Long Focus Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.3M Buy
23,500,000
+7,484,279
+47% +$7.07M 0.49% 48
2026
Q1 		$14.7M Buy
16,015,721
+3,337,318
+26% +$4.04M 0.39% 58
2025
Q4 		$16.2M Buy
12,678,403
+1,315,599
+12% +$1.77M 0.43% 54
2025
Q3 		$14.8M Buy
11,362,804
+1,292,804
+13% +$1.69M 0.49% 50
2025
Q2 		$12.1M Buy
10,070,000
+3,370,000
+50% +$3.74M 0.46% 54
2025
Q1 		$7.24M Buy
+6,700,000
New +$9.41M 0.24% 65

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Long Focus Capital Management's LAB Position: Q2 2026 in Review

Long Focus Capital Management increased its Standard BioTools (LAB) stake by 47% in Q2 2026, buying an estimated $7.07M and bringing the position to 23,500,000 shares worth $19.3M. The position accounts for 0.49% of the portfolio, ranked #48.

Long Focus Capital Management first reported a position in LAB in Q1 2025 and has held it in 6 quarters since. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Long Focus Capital Management held 23,500,000 shares of Standard BioTools worth $19.3M as of Q2 2026.
  • Long Focus Capital Management bought 7,484,279 Standard BioTools shares in Q2 2026, an estimated $7.07M.
  • Standard BioTools made up 0.49% of Long Focus Capital Management's portfolio in Q2 2026, its #48 holding.
  • Long Focus Capital Management first reported a position in Standard BioTools in Q1 2025 and has held it in 6 quarters since.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Long Focus Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.